CD52 and hemophagocytic syndrome: Studies have demonstrated that the JAK inhibitor ruxolitinib can alleviate the symptoms of secondary HLH in adults.[4]According to Rebecca et al,[10] alemtuzumab, a CD52 antibody against T cell and tissue cell expression, was effective in treating refractory HLH in children and adults.